# Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

> **NCT02981966** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 32 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02981966
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-23
- **Primary completion:** 2022-04-30
- **Final completion:** 2023-05-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981966, "Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02981966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*